UK markets close in 4 hours 10 minutes
  • FTSE 100

    7,009.80
    -11.15 (-0.16%)
     
  • FTSE 250

    17,634.12
    -88.71 (-0.50%)
     
  • AIM

    826.46
    -1.43 (-0.17%)
     
  • GBP/EUR

    1.1215
    +0.0106 (+0.95%)
     
  • GBP/USD

    1.0805
    +0.0122 (+1.14%)
     
  • BTC-GBP

    18,715.79
    +1,041.08 (+5.89%)
     
  • CMC Crypto 200

    461.42
    +28.32 (+6.54%)
     
  • S&P 500

    3,655.04
    -38.19 (-1.03%)
     
  • DOW

    29,260.81
    -329.60 (-1.11%)
     
  • CRUDE OIL

    77.83
    +1.12 (+1.46%)
     
  • GOLD FUTURES

    1,645.10
    +11.70 (+0.72%)
     
  • NIKKEI 225

    26,571.87
    +140.32 (+0.53%)
     
  • HANG SENG

    17,860.31
    +5.17 (+0.03%)
     
  • DAX

    12,300.80
    +72.88 (+0.60%)
     
  • CAC 40

    5,805.89
    +36.50 (+0.63%)
     

The Biotech Growth Trust Plc - Transaction in Own Shares

·1-min read

For immediate release

26 August 2022

THE BIOTECH GROWTH TRUST PLC

(the "Company")

MARKET PURCHASE OF COMPANY’S OWN SHARES

Notification is given, pursuant to the authority granted at Annual General Meeting of the Company held on 19 July 2022 to make market purchases of the Company’s own shares up to an aggregate maximum of 6,134,167 that a market total of 200,000 Ordinary shares of 25p each in the capital of the Company were purchased today for cancellation by the Company at a price of 992.99 pence per share.

Following this transaction and in conformity with the provisions of the Transparency Directive, the Company hereby notifies the market that the total number of Ordinary shares that the Company has in issue, less the total number of Ordinary shares bought back for cancellation by the Company following such purchase, and therefore, the total number of voting rights in the Company is 40,476,330. The Company does not currently hold any Ordinary shares in treasury.

The figure of 40,476,330 may be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.

For and on behalf of

Frostrow Capital LLP

Company Secretary

For further information, please contact:

Mark Pope

Frostrow Capital LLP

Tel: 020 3 170 4913